Drugs / EDP-788
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02255968 | Aug → Oct 2014 | — | Enanta Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT01999725 | Jan → Sep 2014 | — | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-01-13 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 enanta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02255968 ↗ |
| Route | Oral | “single doses of orally administered EDP-788” NCT01999725 ↗ |